Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. has announced its 2025 second extraordinary general meeting (EGM) scheduled for April 2, 2025, where the primary agenda is to consider and approve the appointment of Mr. Wen Qingkai as an executive director. This appointment could potentially influence the company’s strategic direction and governance, impacting stakeholders and possibly enhancing its industry positioning.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on developing innovative therapies and products, with a market emphasis on biopharmaceutical advancements.
YTD Price Performance: 8.89%
Average Trading Volume: 2,364,601
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$14.88B
See more data about 9995 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “They Read Like a Cry for Help”, Starbucks Stock (NASDAQ:SBUX) Notches Up Despite Cup Note Concerns
- “The Merger of Marketing and Tech has Never Been Greater”: Home Depot Stock (NYSE:HD) Swings Up With Growing Marketing Plans
- Why Arista Networks Stock (ANET) Is Down Today and Why Morgan Stanley Says ‘Take the Plunge’